Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

Protocol No
SWOG-S2012
Staff Member
Alexandria T Phan
Phase
II/III
Summary

The purpose of this study is to compare the usual treatment alone to using atezolizumab plus the usual treatment. Another purpose is to compare using atezolizumab just at the beginning of treatment to continuing it beyond the initial treatment. The addition of atezolizumab to the usual treatment could help patients live longer. But it could also cause side effects, which are described in the risks section below.

This study will help the study doctors find out if this different approach is better or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study approach increases the life of patients by six months or more compared to the usual approach.
Objective
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Colorectal, Other Gastrointestinal, Prostate, Pancreas/Liver, Ovary, Early Phase/Multiple Disease Site Cancers, Bladder, Prostate and Urologic Cancers, Gynecologic Cancers, Gastrointestinal Cancers
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT05058651